HORMONE / IN CLINICAL TRIALS
CJC-1295
Subcutaneous injection
Overview
A synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days.
Mechanism of Action
CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
​Research Summary & Key Findings
Phase II clinical data showed sustained 2-3 fold increases in GH and IGF-1 levels for 6+ days after a single injection. Well-tolerated with dose-dependent effects on body composition parameters including lean mass gains.
Clinical Status
FDA APPROVED
CJC-1295 is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
Subcutaneous injection
Administration Routes
METABOLIC
Semaglutide (Ozempic/Wegovy)
METABOLIC
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.